IL5 and asthma: New biologics that target IL-5 signaling (anti-IL-5 [mepolizumab, reslizumab] and anti-IL-5 receptor α [benralizumab]) reduce the rate of asthma exacerbations in patients with severe eosinophilic asthma [2].